Ozempic and Wegovy, widely used medications for diabetes and weight loss, show a slightly elevated risk for a rare vision condition that causes sudden vision loss, according to Rutgers researchers. The condition can potentially result in permanent sight damage.
GLP-1 receptor agonists like these drugs have surged in popularity as millions of people use them for glucose control and weight management. The research team identified an association between these medications and increased risk, though the absolute risk remains very low.
The findings come as use of GLP-1 drugs continues to expand globally. Rutgers researchers emphasize that despite the small risk, the connection warrants clinical attention given the massive scale of current and future GLP-1 use. The sudden nature of potential vision loss makes awareness particularly important for patients and healthcare providers.
The specific condition linked to these medications remains rare enough that the overall safety profile of GLP-1 drugs does not change dramatically. However, the research suggests that people taking Ozempic, Wegovy, and similar medications should maintain awareness of vision changes as a potential side effect. Medical supervision and prompt reporting of visual symptoms become especially important for this population.
The study adds to ongoing monitoring of GLP-1 medications as their use expands beyond their original indications. Healthcare providers can now incorporate discussion of this rare vision risk into informed consent conversations with patients starting these drugs. Patients experiencing sudden vision changes should seek immediate medical evaluation.